Posted from: Thursday, May 05, 2016 - 12:31 PM - Present

BromSite Approved for post Cataract Surgery

April 11, 2016 – The FDA approved BromSite™ (bromfenac ophthalmic solution) 0.075% to be used after surgery for cataracts. BromSite, manufactured by Sun Pharmaceuticals, is a topical non-steroidal anti-inflammatory drug (NSAID) intended to prevent pain and reduce inflammation in the affected eye. Bromfenac ophthalmic solution is available as both a brand and a generic product, but neither offers the same strength as BromSite. BromSite also uses a patented polymer base to increase the drug’s absorption into the eye and the amount of time the drug remains in contact with the eye. Sun Pharma plans to launch BromSite in the second half of the year.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Saturday, March 25, 2017 - 03:02 AM.